Array Biopharma Inc. (ARRY) Loss Submission Form

The Klein Law Firm notifies shareholders that a class action complaint has been filed on behalf of shareholders of Array Biopharma Inc. (NASDAQ: ARRY) who purchased shares between December 16, 2015 and March 17, 2017. The action, which was filed in the United States District Court for the District of Colorado, alleges that the Company violated federal securities laws.

In particular, the complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that (1) Array’s NEMO study failed to show sufficient clinical benefit of the binimetinib NDA in use for patients with NRAS-mutant melanoma; (2) Array was aware that this lack of supporting data would not be sufficient to receive FDA approval of binimetinib in use for patients with NRAS-mutant melanoma; and (3) as a result of the foregoing, Array’s public statements were materially false and misleading at all relevant times.

Shareholders have until January 22, 2018 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.

Please fill out the form to learn more

Keep Me Informed

The Klein Law Firm does not share your information with others. There is no cost or obligation. This submission does not create an attorney-client relationship. If we believe that you might be an appropriate lead plaintiff, we will contact you to discuss whether to establish an attorney-client relationship.

I am ready to join the action

This letter confirms that you have retained The Klein Law Firm to represent you as a named plaintiff in a shareholder action involving Array Biopharma Inc.

We agree to advance all expenses in the litigation, which means that you are not liable to pay any of the expenses of the lawsuit, whether attorneys' fees or costs. Regardless of the result, we will never ask you to directly pay for any attorneys' fees or costs. Should we obtain a favorable result, we may ask the court to award us compensation to be paid by the defendants or as a portion of any class benefit, but, again, we will never ask you to directly pay any of the costs of this litigation.

As the client you are entitled to direct the litigation in any way you deem proper, and may at any time order us to dismiss the case or opt-out. Should you choose to do so, we will never ask you to reimburse us directly for any legal fees or expenses. During the course of this litigation, we may employ and/or work with other law firms to prosecute your case.

We look forward to representing you and other Array Biopharma Inc. shareholders.

Sincerely,

The Klein Law Firm

Joseph Klein

AGREED: Sign Name Clear